Novavax expects to request federal authorization for its vaccine this summer after it completes final chemistry, manufacturing and control requirements.
In first federal ruling on vaccine mandates, judge sides with Houston hospital, dismissing claims from staff resisters
Pfizer and its German partner BioNTech did not receive federal funding to develop their vaccine, but they did get nearly $2 billion to support its manufacturing and distribution. Moderna received about $2.5 billion, which included support for development as well as manufacturing and distribution of its first 100 million doses.
The government has now bought 300 million doses each of the Pfizer-BioNTech and Moderna vaccines and 200 million of the J&J vaccine. So far, 169 million doses of Pfizer-BioNTech, 129 million doses of the Moderna shots and 11.5 million doses of J&JThe Novavax vaccine, which was supported with $1.6 billion in federal funds for its first 100 million doses, is based on a third type of vaccine technology in which the protein antigen is delivered directly into the body inside tiny particles.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its COVID-19 shot was highly effective against the disease and also protected against variants in a large study in the U.S. and Mexico, potentially offering the world yet another weapon against the virus at a time when developing countries are desperate for doses. While demand for COVID-19 shots in the U.S. has dropped off dramatically and the country has more than enough doses to go around, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting supplies in poor parts of the world.
Read more »
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said.
Read more »
Novavax COVID-19 vaccine more than 90% effective in U.S. trialNovavax Inc (NVAX.O) on Monday reported late-stage data from its U.S.-based clinical trial showing its vaccine is more than 90% effective against COVID-19 across a variety of variants of the virus.
Read more »
Novavax announces its COVID-19 vaccine is over 90% effective against symptomatic diseaseJUST IN: American biotechnology company Novavax announces that its experimental COVID-19 vaccine is more than 90% effective against symptomatic disease in late-stage clinical trials.
Read more »
Novavax Covid vaccine shows over 90 percent efficacy, drugmaker saysCompany says study of nearly 30,000 volunteers in US and Mexico shows its vaccine protects against variants and will seek authorisation by the third quarter of 2021.
Read more »
Novavax Reports Over 90% Efficacy For Its Covid Vaccine—Including Against VariantsThe Maryland-based company's vaccine was also found to be 100% effective at preventing moderate and severe cases of the disease.
Read more »